Metformin is named as an intervention in 31 current clinical trials in our China, USA, UK, India and Ireland registers. 14 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Peking University Third Hospital (3). The most-studied condition is Obesity.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Liraglutide Treatment in Obese Infertile PCOS Women
NCT06742710 · ClinicalTrials.gov ↗ · PCOS, Obesity, Infertility
|
Phase 4 | Recruiting | Peking University Third Hospital | China |
|
Metformin in Post Chronic Pancreatitis Diabetes Mellitus
NCT06937294 · ClinicalTrials.gov ↗ · Chronic Pancreatitis
|
Phase 4 | Recruiting | Changhai Hospital | China |
|
Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.
NCT07019012 · ClinicalTrials.gov ↗ · T2DM
|
Phase 4 | Recruiting | Huazhong University of Science and Technology | China |
|
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
NCT07244003 · ClinicalTrials.gov ↗ · T2DM (Type 2 Diabetes Mellitus)
|
Phase 4 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | China |
|
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
NCT07045142 · ClinicalTrials.gov ↗ · Schizophrenia
|
Phase 3 | Recruiting | Central South University | China |
|
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
NCT07092618 · ClinicalTrials.gov ↗ · Longevity, GLP-1, Geroscience
|
Phase 2/3 | Recruiting | AgelessRx | USA |
|
Acupuncture or Metformin for Insulin Resistance in Women With PCOS
NCT02647827 · ClinicalTrials.gov ↗ · Polycystic Ovary Syndrome, Insulin Resistance, Hyperandrogenism
|
Phase 2 | Recruiting | Karolinska Institutet | China |
|
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03424005 · Metastatic Breast Cancer
|
Phase 1/2 | Recruiting | Hoffmann-La Roche | UK, USA |
|
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139 · ClinicalTrials.gov ↗ · Breast Cancer, Solid Tumors, Adult
|
Phase 1/2 | Recruiting | Eli Lilly and Company | Ireland, USA |
|
Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia
NCT07188740 · ClinicalTrials.gov ↗ · DNMT3A Gene Mutation
|
Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
A Study of LY4515100 in Healthy Participants
NCT07339722 · ClinicalTrials.gov ↗ · Healthy
|
Phase 1 | Recruiting | Eli Lilly and Company | USA |
|
Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial
NCT06863532 · ClinicalTrials.gov ↗ · Type 2 Diabetes
|
Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
|
Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis.
NCT07108075 · Liver Cirrhosis
|
Not applicable | Recruiting | Institute of Liver and Biliary Sciences, India | India |
|
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
NCT07293325 · ClinicalTrials.gov ↗ · Adults With Simple Obesity
|
Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
|
Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
NCT06762223 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus
|
Phase 4 | Not yet open | Xiqiao Zhou | China |
|
The Effect of Semaglutide on Bone Health
NCT07165158 · ClinicalTrials.gov ↗ · Osteoporosis, Osteoporosis Fracture, T2DM
|
Phase 4 | Not yet open | The First Affiliated Hospital of Xiamen University | China |
|
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
NCT07502001 · ClinicalTrials.gov ↗ · Overweight, Obesity
|
Phase 1 | Not yet open | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | China |
|
Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body
NCT07753252 · ClinicalTrials.gov ↗ · Healthy Participants
|
Phase 1 | Not yet open | Bayer | USA |
|
Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity
NCT06775093 · ClinicalTrials.gov ↗ · Polycystic Ovary Syndrome, Obesity, Infertility, Female
|
Not applicable | Not yet open | Peking University Third Hospital | China |
|
Effects of Cofrogliptin on Beta-Cell Function in LADA Patients
NCT07460336 · ClinicalTrials.gov ↗ · Latent Autoimmune Diabetes in Adults (LADA)
|
Not applicable | Not yet open | Second Xiangya Hospital of Central South University | China |
|
Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOS
NCT07687667 · ClinicalTrials.gov ↗ · Polycystic Ovary Syndrome (PCOS), Obesity, Infertility, Female
|
Not applicable | Not yet open | Peking University Third Hospital | China |
|
Efficacy and Safety of Hebenrun in Patients With Type 2 Diabetes
NCT07768280 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus
|
Not applicable | Not yet open | Jiangxi University of Traditional Chinese Medicine | China |
|
Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD
NCT07778719 · ClinicalTrials.gov ↗ · Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
|
Not applicable | Not yet open | The 95th Hospital of Putian๏ผPutian, Fujian, China | China |
|
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
NCT06959784 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular Disease
|
Phase 4 | By invitation | China-Japan Friendship Hospital | China |
|
Study of Time-restricted Eating (TRE) to Clinical Pregnancy Rate in PCOS Women With Glucose Metabolism Disorder Via IVF/ICSI
NCT06666933 · ClinicalTrials.gov ↗ · PCOS, Glucose Metabolism Disorder, IVF Outcome
|
Not applicable | By invitation | RenJi Hospital | China |
|
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
NCT06257966 · ClinicalTrials.gov ↗ · Type2 Diabetes Mellitus
|
Phase 3 | Active, closed | Beijing Dongfang Biotech Co., Ltd. | China |
|
Combination Gerotherapeutic Interventions for Healthspan Improvement
NCT07475546 · Healthspan Improvement, Aging, Longevity
|
Phase 3 | Active, closed | AgelessRx | USA |
|
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
NCT02365597 · ClinicalTrials.gov ↗ · Urothelial Cancer
|
Phase 2 | Active, closed | Janssen Research & Development, LLC | UK, USA, India |
|
The Effect of Metformin in Patients With Newly Diagnosed mHSPC
NCT04925063 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer
|
Phase 2 | Active, closed | Sun Yat-sen University | China |
|
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
NCT03006172 · ClinicalTrials.gov ↗ · Breast Cancer, Solid Tumor
|
Phase 1 | Active, closed | Genentech, Inc. | UK, USA |
|
Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin
NCT07362030 · ClinicalTrials.gov ↗ · Obesity
|
Phase 1 | Active, closed | Guangdong Raynovent Biotech Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Obesity | 5 |
| Breast Cancer | 2 |
| Aging | 2 |
| Longevity | 2 |
| Infertility, Female | 2 |
| T2DM | 2 |
| Type 2 Diabetes | 2 |
| Type 2 Diabetes Mellitus | 2 |
| Polycystic Ovary Syndrome | 2 |
| PCOS | 2 |
| Solid Tumors, Adult | 1 |
| Metastatic Breast Cancer | 1 |
| Solid Tumor | 1 |
| Urothelial Cancer | 1 |
| Healthspan Improvement | 1 |
| Healthy | 1 |
| GLP-1 | 1 |
| Geroscience | 1 |
| Healthy Participants | 1 |
| Liver Cirrhosis | 1 |
| T2DM (Type 2 Diabetes Mellitus) | 1 |
| Adults With Simple Obesity | 1 |
| Polycystic Ovary Syndrome (PCOS) | 1 |
| Type2 Diabetes Mellitus | 1 |
| Schizophrenia | 1 |
| DNMT3A Gene Mutation | 1 |
| Diabetes Mellitus | 1 |
| Cardiovascular Diseases | 1 |
| Cerebrovascular Disease | 1 |
| Osteoporosis | 1 |
| Osteoporosis Fracture | 1 |
| Metastatic Prostate Cancer | 1 |
| Chronic Pancreatitis | 1 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | 1 |
| Overweight | 1 |
| Infertility | 1 |
| Metabolic Dysfunction-associated Steatotic Liver Disease | 1 |
| Glucose Metabolism Disorder | 1 |
| IVF Outcome | 1 |
| Latent Autoimmune Diabetes in Adults (LADA) | 1 |
| Insulin Resistance | 1 |
| Hyperandrogenism | 1 |
| Lead sponsor | Trials |
|---|---|
| Peking University Third Hospital | 3 |
| Eli Lilly and Company | 2 |
| AgelessRx | 2 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| Hoffmann-La Roche | 1 |
| Genentech, Inc. | 1 |
| Janssen Research & Development, LLC | 1 |
| Bayer | 1 |
| Institute of Liver and Biliary Sciences, India | 1 |
| Huazhong University of Science and Technology | 1 |
| Beijing Dongfang Biotech Co., Ltd. | 1 |
| Central South University | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| China-Japan Friendship Hospital | 1 |
+ 10 more sponsors in the trial list above.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 22 | 9 |
| Clinical trials in USA | 8 | 4 |
| Clinical trials in UK | 3 | 1 |
| Clinical trials in India | 2 | 1 |
| Clinical trials in Ireland | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
31 current trials in our China, USA, UK, India and Ireland registers name Metformin as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 14 of the 31 trials are recruiting: 9 with sites in China, 4 with sites in USA, 1 with sites in UK, 1 with sites in India and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Peking University Third Hospital (3), Eli Lilly and Company (2), AgelessRx (2) and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd (2), among 25 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Metformin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Metformin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Metformin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.